Imm-h007 is an adenosine derivative that is an activator of the AMP-Activated Protein Kinase (AMPK). Imm-h007 is a potential drug for the treatment of cardiac insufficiency. Imm-h007 negatively regulates endothelial inflammation by inactivating NF-κB and JNK/AP1 signaling. Imm-h007 can inhibit the degradation of ABCA1 (ATP binding cassette subfamily a member 1) and promote its cell surface localization in macrophages, thus promoting cholesterol efflux.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 60 mg/mL|
|Related AMPK Products|
ASP4132 is an orally active, potent AMPK activator with an EC50 of 18 nM and anticancer activity that promotes tumor regression in a xenograft mouse model of breast cancer.
Mk-8722 is a potent, direct, PAN-AMPK allosteric activator.
BC1618, an orally active Fbxo48 inhibitor, stimulates Ampk signaling (preventing activated pAmpkα from being degraded by fBXO48-mediated proteasome). BC1618 promotes mitochondrial division, autophagy and insulin sensitivity in the liver.
O-304 is a pioneering, orally active pan-AMPK activator that increases AMPK activity by inhibiting dephosphorylation of pAMPK.
IM156, a metformin derivative, is an oxidative phosphorylation inhibitor that increases AMPK phosphorylation.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.